Lakefront Biotherapeutics (LKFT) Research & Development (2016 - 2026)
Lakefront Biotherapeutics (LKFT) reported Research & Development of -$36.2 million for Q1 2026, up 81.14% year-over-year from -$20.0 million in Q1 2025, and down 103.84% quarter-over-quarter from $944.4 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Research & Development (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 11 years of Research & Development data on file, last reported at -$36.2 million in Q1 2026.
- Research & Development for Q1 2026 came in at -$36.2 million, up 81.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $704.1 million (up 197.67% YoY), and the FY2025 annual result was $534.8 million, up 49.19% from the prior year.
- Research & Development eased to -$36.2 million in Q1 2026 per LKFT's latest filing, from $944.4 million in the prior quarter.
- Over five years, Research & Development peaked at $944.4 million in Q4 2025 and troughed at -$396.8 million in Q3 2025.
- A 5-year average of $137.0 million and a median of -$36.2 million in 2026 frame the typical range for Research & Development.
- On a YoY basis, Research & Development climbed as much as 196.58% in 2025 and fell as far as 147.09% in 2025.
- A 5-year view of Research & Development shows it stood at $646.7 million in 2022, then plunged by 32.04% to $439.5 million in 2023, then soared by 39.49% to $613.1 million in 2024, then surged by 54.04% to $944.4 million in 2025, then tumbled by 103.84% to -$36.2 million in 2026.
- Business Quant data shows LKFT's Research & Development at -$36.2 million in Q1 2026, $944.4 million in Q4 2025, and -$396.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -58.00 Mn |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | -36.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.25 Mn |
| Dec 31, 2025 | 944.42 Mn |
| Sep 30, 2025 | -396.77 Mn |
| Jun 30, 2025 | 192.70 Mn |
| Mar 31, 2025 | -192.23 Mn |
| Dec 31, 2024 | 613.08 Mn |
| Sep 30, 2024 | -249.29 Mn |
| Jun 30, 2024 | 64.97 Mn |
| Mar 31, 2024 | -77.80 Mn |
| Dec 31, 2023 | 439.53 Mn |
| Mar 31, 2023 | -56.41 Mn |
| Dec 31, 2022 | 646.70 Mn |
| Mar 31, 2022 | -112.15 Mn |
| Jun 30, 2021 | -167.23 Mn |
| Mar 31, 2021 | -156.76 Mn |
| Jun 30, 2020 | -162.41 Mn |
| Mar 31, 2020 | -128.90 Mn |
| Dec 31, 2019 | 795.12 Mn |
| Sep 30, 2019 | -134.28 Mn |
| Jun 30, 2019 | -106.04 Mn |